The CEO (CEO) of Pfizer, Albert Bourla, has given up 61.8% of its shares in the pharmaceutical. The news coincides with the announcement made on Monday by the laboratory about the effectiveness of the covid-19 vaccine, which it develops together with Biontech, as recorded in the records of the American Securities Market Commission (SEC, for its acronym in English ).
Pfizer’s CEO put for sale last monday a total of 132,508 shares of the company at a unit price of $ 41.94, which is equivalent to 5,557 million dollars (4,727 million euros).
Before the vaccine announcement
The Friday before the announcement of the hopeful results of its vaccine trials, Pfizer shares had dismissed the session at $ 36.40, more than a 13% below the sale price of Bourla shares.
After the operation, the CEO of Pfizer directly holds a shareholding package of 78,273 shares in the company, in addition to another 3,539 indirectly.
On the other hand, the records of the US National Securities Market Commission (CNMV) also confirm the sale by Sally Susman, Vice President of Pfizer, of a shareholding package of 43,662 shares at a unit price of $ 41.94, which equates to a total of $ 1,831 million (1,557 million euros).
Susman holds a direct interest of 108,096 shares in the company and indirectly controls another 708 Pfizer shares.
Guaranteed operations in the market
The transaction would be supported by rule 10b5-1 of the US stock market, which sets the conditions for executives of listed companies to operate without violating the rules on the use of inside information.
In this sense, the pharmaceutical company indicated that the transaction had been authorized in advance by Bourla on August 19 within the framework of the company’s share management program.